Terlipressin in Cirrhotic Liver Patients For Early Detection Of Acute Kidney Injury Guided By Plasma NGAL Marker
Not Applicable
Not yet recruiting
- Conditions
- Circulatory SystemLiver cirrhosis
- Registration Number
- PACTR201704002184280
- Lead Sponsor
- The memorial Souad kafafi university hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Circulatory dysfunction due to bacterial infection.
- hypovolemia secondary to gastrointestinal bleeding, paracentesis or diuretic use.
Exclusion Criteria
- History of coronary artery disease
- Cardiac arrhythmias
- Cardiomyopathies
- Obliterative arterial disease of the lower limbs
- Asthma
- Chronic obstructive pulmonary disease
- Cerebrovascular disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does terlipressin utilize to detect acute kidney injury in cirrhotic patients via plasma NGAL?
How does terlipressin compare to standard-of-care treatments in early detection of acute kidney injury in liver cirrhosis?
Which biomarkers other than plasma NGAL are predictive of acute kidney injury in cirrhotic liver patients?
What are the potential adverse events associated with terlipressin use in cirrhotic patients and how are they managed?
Are there combination therapies or competitor drugs that enhance terlipressin's efficacy in detecting acute kidney injury in liver cirrhosis?